<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p20" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_20{left:130px;bottom:1195px;letter-spacing:0.22px;}
#t2_20{left:804px;bottom:1195px;letter-spacing:0.13px;}
#t3_20{left:128px;bottom:1109px;letter-spacing:-0.18px;}
#t4_20{left:238px;bottom:1109px;letter-spacing:-0.22px;}
#t5_20{left:258px;bottom:1083px;letter-spacing:-0.19px;}
#t6_20{left:238px;bottom:1054px;letter-spacing:-0.01px;}
#t7_20{left:238px;bottom:1035px;letter-spacing:-0.01px;}
#t8_20{left:238px;bottom:1015px;letter-spacing:-0.01px;}
#t9_20{left:238px;bottom:996px;letter-spacing:-0.01px;}
#ta_20{left:238px;bottom:961px;letter-spacing:-0.01px;}
#tb_20{left:238px;bottom:942px;letter-spacing:-0.01px;}
#tc_20{left:238px;bottom:922px;letter-spacing:-0.01px;}
#td_20{left:238px;bottom:888px;letter-spacing:-0.01px;}
#te_20{left:238px;bottom:868px;letter-spacing:-0.01px;}
#tf_20{left:238px;bottom:849px;letter-spacing:-0.01px;}
#tg_20{left:238px;bottom:814px;letter-spacing:-0.01px;}
#th_20{left:238px;bottom:795px;letter-spacing:-0.01px;}
#ti_20{left:238px;bottom:775px;letter-spacing:-0.01px;}
#tj_20{left:238px;bottom:756px;letter-spacing:-0.01px;}
#tk_20{left:238px;bottom:736px;letter-spacing:-0.01px;}
#tl_20{left:238px;bottom:717px;letter-spacing:-0.01px;}
#tm_20{left:238px;bottom:697px;letter-spacing:-0.01px;}
#tn_20{left:238px;bottom:678px;letter-spacing:-0.01px;}
#to_20{left:238px;bottom:659px;letter-spacing:-0.01px;}
#tp_20{left:238px;bottom:639px;letter-spacing:-0.01px;}
#tq_20{left:238px;bottom:585px;letter-spacing:-0.01px;}
#tr_20{left:238px;bottom:566px;letter-spacing:-0.01px;}
#ts_20{left:238px;bottom:546px;letter-spacing:-0.01px;}
#tt_20{left:238px;bottom:527px;letter-spacing:-0.01px;}
#tu_20{left:238px;bottom:507px;letter-spacing:-0.01px;}
#tv_20{left:238px;bottom:488px;letter-spacing:-0.01px;}
#tw_20{left:238px;bottom:468px;letter-spacing:-0.01px;}
#tx_20{left:238px;bottom:449px;letter-spacing:-0.01px;}
#ty_20{left:238px;bottom:430px;letter-spacing:-0.01px;}
#tz_20{left:238px;bottom:410px;letter-spacing:-0.01px;}
#t10_20{left:238px;bottom:391px;letter-spacing:-0.01px;}
#t11_20{left:238px;bottom:317px;letter-spacing:-0.01px;}
#t12_20{left:238px;bottom:298px;letter-spacing:-0.01px;}
#t13_20{left:238px;bottom:278px;letter-spacing:-0.01px;}
#t14_20{left:238px;bottom:259px;letter-spacing:-0.01px;}
#t15_20{left:238px;bottom:239px;letter-spacing:-0.01px;}
#t16_20{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_20{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_20{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_20{font-size:18px;font-family:NotoSans-Regular_7j-;color:#000;}
.s3_20{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
.s4_20{font-size:13px;font-family:NotoSans-Regular_7j-_1;color:#000;}
.s5_20{font-size:11px;font-family:NotoSans-Regular_7j-_1;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts20" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

@font-face {
	font-family: NotoSans-Regular_7j-_1;
	src: url("fonts/NotoSans-Regular_7j-_1.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg20Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg20" style="-webkit-user-select: none;"><object width="908" height="1286" data="20/20.svg" type="image/svg+xml" id="pdf20" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_20" class="t s0_20">2.2. Basics of the methodology </span><span id="t2_20" class="t s1_20">20 </span>
<span id="t3_20" class="t s2_20">2.2.5. </span><span id="t4_20" class="t s2_20">Independence and explanation of possible </span>
<span id="t5_20" class="t s2_20">Conflicts of interest </span>
<span id="t6_20" class="t s3_20">The German Cancer Aid provided the financial resources within the framework of the Oncology </span>
<span id="t7_20" class="t s3_20">Guidelines Program (OL). These funds were used for personnel costs, office supplies, literature </span>
<span id="t8_20" class="t s3_20">procurement and the two consensus conferences (room rental, technology, catering, moderator </span>
<span id="t9_20" class="t s3_20">fees, travel expenses for participants). </span>
<span id="ta_20" class="t s3_20">Travel expenses were reimbursed in accordance with the Federal Travel Act and the guidelines </span>
<span id="tb_20" class="t s3_20">used by the DKG. The guideline was drawn up with editorial independence from the funding </span>
<span id="tc_20" class="t s3_20">organization. </span>
<span id="td_20" class="t s3_20">Funds from the German Cancer Aid were available for the evidence analysis and methodological </span>
<span id="te_20" class="t s3_20">support. The guideline coordinators and all other experts involved received no remuneration for </span>
<span id="tf_20" class="t s3_20">their guideline work. </span>
<span id="tg_20" class="t s3_20">At the beginning of the guideline process, all members submitted a written declaration of any </span>
<span id="th_20" class="t s3_20">conflicts of interest that may exist. The AWMF form was used (the mandate holders were </span>
<span id="ti_20" class="t s3_20">questioned according to the categories of the AWMF form on expert/advisory activities, third- </span>
<span id="tj_20" class="t s3_20">party funded research, patents, schools/scientific interests, personal relationships/ownership of </span>
<span id="tk_20" class="t s3_20">business shares and membership of relevant organizations). During the course of the </span>
<span id="tl_20" class="t s4_20">guideline's development, individual mandate holders submitted an update. At the beginning of </span>
<span id="tm_20" class="t s4_20">both consensus conferences, the possibility of a conflict of interest was discussed in plenary on </span>
<span id="tn_20" class="t s4_20">the basis of the individual declarations. The query on expert/advisory activities was specified for </span>
<span id="to_20" class="t s4_20">the areas of the oropharynx and larynx, and the query on lectures was specified for the area of </span>
<span id="tp_20" class="t s4_20">the larynx. </span>
<span id="tq_20" class="t s4_20">The conflict of interest declaration of the guideline coordinator was forwarded to the OL Office </span>
<span id="tr_20" class="t s4_20">for review, the others were reviewed by the guideline coordinator. At the first consensus </span>
<span id="ts_20" class="t s4_20">meeting on July 14, 2016 in Berlin, it was determined that mandate holders who have led </span>
<span id="tt_20" class="t s4_20">studies on specific topics of laryngeal carcinoma should not vote on the corresponding </span>
<span id="tu_20" class="t s4_20">statements and recommendations: They could, however, provide documents and further </span>
<span id="tv_20" class="t s4_20">information and participate in the discussion. Third-party funding from industry and advisory </span>
<span id="tw_20" class="t s4_20">boards should be stated. The company name (third-party funding) should be mentioned. When </span>
<span id="tx_20" class="t s4_20">providing information on third-party funding, it should be made clear which company it came </span>
<span id="ty_20" class="t s4_20">from and what it was spent on. People who have received third-party funding from industry that </span>
<span id="tz_20" class="t s4_20">is related to laryngeal carcinoma or who belong to an advisory board that is associated with this </span>
<span id="t10_20" class="t s4_20">indication should not vote on the statements and recommendations affected by this. </span>
<span id="t11_20" class="t s4_20">The voting rules were implemented in the consensus conferences as agreed: Prof. Dr. Fietkau </span>
<span id="t12_20" class="t s4_20">abstained from voting on the topics of supportive nutritional therapies and chemotherapy for </span>
<span id="t13_20" class="t s4_20">relapses due to his research activities. Prof. Budach and Mr. Fietkau abstained from questions </span>
<span id="t14_20" class="t s4_20">relating to the active ingredient cetuximab. A total of 5 of the experts present abstained from </span>
<span id="t15_20" class="t s4_20">voting on the recommendation on PD-1 inhibitors due to conflicts of interest. </span>
<span id="t16_20" class="t s5_20">Â© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
